Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 7/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2743292 | 0.81 | KDM4E (0.58) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL202005 | 0.78 | KDM4E (0.42) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL1104756 | 0.75 | ALDH1A1 (0.54) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL31249024 | 0.68 | KDM4E (0.61) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL202430 | 0.68 | NOS2 (0.44) | KDM4EALDH1A1POLBHTR2AHTR2C | |
| SCHEMBL1104767 | 0.67 | KDM4E (0.56) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL203571 | 0.67 | KDM5B (0.39) | KDM4E | |
| SCHEMBL205143 | 0.66 | KDM4E (0.40) | KDM4EALDH1A1POLB | |
| SCHEMBL1232959 | 0.66 | JAK2 (0.36) | ALDH1A1 | |
| SCHEMBL14644488 | 0.65 | JAK1 (0.37) | KDM4EALDH1A1HPGDHSD17B10HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088788-B2 | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | IL2, IFNG, IL4 | KDM4E 2419/4885ALDH1A1 979/4885HPGD 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.